MDxHealth Reports Q1-2024 Results and Announces Growth Capital from OrbiMed
May 01, 2024 07:45 ET
|
mdxhealth
MDxHealth Reports Q1-2024 Results and Announces Growth Capital from OrbiMed Year-over-year Q1 revenues increase by 35% to $19.8 millionIncreasing 2024 revenue guidance to $83-85 million, previously...
Opthea Announces Upcoming Presentations at the Retina World Congress 2024
May 01, 2024 07:30 ET
|
Opthea Limited
MELBOURNE, Australia and PRINCETON, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...
Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024
May 01, 2024 07:30 ET
|
Ocular Therapeutix, Inc.
First quarter 2024 financial results to be reported on Tuesday, May 7, 2024 Investor Day to replace first quarter 2024 earnings conference call; quarterly calls to resume regular cadence with...
Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024
May 01, 2024 07:30 ET
|
Zevra Therapeutics
CELEBRATION, Fla., May 01, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that it will host a...
AppTech Payments Strategic Partner PayToMe.co Honored with Six American Business Awards® for AI and Technological Excellence
May 01, 2024 07:30 ET
|
AppTech Corp.
CARLSBAD, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- AppTech Payments Corp. (Nasdaq: APCX) (“AppTech” or the “Company”), a pioneering Fintech company powering frictionless commerce, announces that its...
Katapult to Announce First Quarter 2024 Financial Results on May 15, 2024
May 01, 2024 07:30 ET
|
Katapult Holdings, Inc.
Katapult announces date of Q124 Earnings Release
Repligen Reports First Quarter 2024 Financial Results
May 01, 2024 07:30 ET
|
Repligen Corporation
Reports first quarter revenue of $151 million Increased new modalities revenue by 16% year-over-yearIncreased Filtration (non-COVID) revenue by 12% year-over-yearAchieved a nine-month book-to-bill...
Altimmune to Participate at Two Upcoming Conferences
May 01, 2024 07:30 ET
|
Altimmune, Inc
GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at...
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
May 01, 2024 07:30 ET
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Verisk Reports First-Quarter 2024 Financial Results
May 01, 2024 07:15 ET
|
Verisk Analytics, Inc.
• Consolidated revenues were $704 million, up 8.0%, and up 6.9% on an organic constant currency (OCC) basis for the first quarter of 2024. • Income from continuing operations was $219 million,...